ANDA 202393, held by Twi Pharms. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 202393 (Diclofenac Sodium), held by Twi Pharms, was first approved by FDA on Nov 24, 2014, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 24, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium1.5% · solution;topical | Diclofenac Sodium | Discontinued |
| Apr 28, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 1, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 24, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters